Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.
These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twenty-nine of these studies were prospective randomized trials. For the other herpesviruses, HHV-6, -7 and -8, no randomized controlled trial has been performed, although data from some studies with other primary endpoints have been used to assess the management of HHV-6 infection. Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.
Ljungman
P
P
Department of Hematology, Karolinska University Hospital/Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se
de la Camara
R
R
Cordonnier
C
C
Einsele
H
H
Engelhard
D
D
Reusser
P
P
Styczynski
J
J
Ward
K
K
D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000628:therapy / Q000821:virology*; D015654:Herpesvirus 6, Human; D016199:Herpesvirus 7, Human; D019288:Herpesvirus 8, Human; D019349:Roseolovirus Infections / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy*; D012514:Sarcoma, Kaposi / Q000175:diagnosis*; D033581:Stem Cell Transplantation / Q000009:adverse effects